Keywords: Sphingosine 1-phosphate, sphingosine 1-phosphate receptor 3, cardiovascular system
Research progress of sphingosine 1-phosphate receptor 3 in the cardiovascular system
Yangmengna Gao1,2, Ran Yuan1,2, Kecheng Zhai1,2, Hui Su1,2, Renke Sun1,2, Shangping Fang1,2
1School of Anesthesiology, 2Anesthesia Laboratory and Training Center, Wannan Medical College, Wuhu 241002,
Anhui, China.
Address correspondence to: Shangping Fang, Anaesthesiology Experimental Training Center, College of Anesthesiology, Wannan Medical College, No.22 Wenchang West Road, Yijiang District, Wuhu 241002, Anhui, China. Tel:+86-19855362767. E-mail: 20180041@wnmc.edu.cn.
Acknowledgement: Key Project Research Fund of Wannan Medical College (WK2022Z10); National College Student Innovation and Entrepreneurship Project (202310368016); Anhui Province College Student Innovation and Entrepreneurship Project (S202210368107, S202210368108); Student Research Funding Project of Wannan Medical College (WK2023XS10).
DOI: https://doi.org/10.61189/076009mwdtns
Received January 25, 2024; Accepted March 19, 2024; Published Jane 30, 2024
Highlights
● Sphingosine 1-phosphate receptor 3 (S1PR3) promotes the proliferation of vascular endothelial cells and enhances barrier function.
● S1PR3 is a promising target for clinical treatment of cardiac ischemia-reperfusion, cardiac fibrosis and atherosclerosis.
● Fingolimod and other modulators of S1PR3 have shown therapeutic efficacy in phase I and II clinical trials for cardiovascular diseases.
● S1PR3 play crucial roles in the perioperative evaluation and treatment of the cardiovascular system, as well as in sepsis.
Abstract
Keywords: Sphingosine 1-phosphate, sphingosine 1-phosphate receptor 3, cardiovascular system